Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

CymaBay Therapeutics, Inc. (CBAY)

14.68   -0.23 (-1.54%) 10-02 16:00
Open: 14.82 Pre. Close: 14.91
High: 15.175 Low: 14.53
Volume: 1,346,211 Market Cap: 1,654(M)

Technical analysis

as of: 2023-10-02 4:48:58 PM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 19.02     One year: 21.25
Support: Support1: 13.19    Support2: 10.98
Resistance: Resistance1: 16.29    Resistance2: 18.2
Pivot: 15.5
Moving Average: MA(5): 15.01     MA(20): 15.42
MA(100): 11.73     MA(250): 8.63
MACD: MACD(12,26): 0.2     Signal(9): 0.5
Stochastic oscillator: %K(14,3): 23.4     %D(3): 29.9
RSI: RSI(14): 49.6
52-week: High: 18.2  Low: 3.15
Average Vol(K): 3-Month: 2,120 (K)  10-Days: 2,141 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CBAY ] has closed above bottom band by 29.2%. Bollinger Bands are 29.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 15.19 - 15.27 15.27 - 15.34
Low: 14.33 - 14.43 14.43 - 14.52
Close: 14.53 - 14.68 14.68 - 14.81

Company Description

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Headline News

Sat, 30 Sep 2023
Kurt Von Emster Sells 15921 Shares of CymaBay Therapeutics, Inc ... - MarketBeat

Tue, 26 Sep 2023
UBS Maintains Cymabay Therapeutics (CBAY) Buy Recommendation - Nasdaq

Tue, 26 Sep 2023
Should You Hold CymaBay Therapeutics Inc (CBAY) in Biotechnology Industry? - InvestorsObserver

Sun, 24 Sep 2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Given Consensus ... - MarketBeat

Thu, 21 Sep 2023
CymaBay Therapeutics Launches Confirmatory Study for Seladelpar ... - Best Stocks

Mon, 11 Sep 2023
Why CymaBay Therapeutics Stock Popped Again Today - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 113 (M)
Shares Float 89 (M)
% Held by Insiders 0.3 (%)
% Held by Institutions 92.8 (%)
Shares Short 8,960 (K)
Shares Short P.Month 11,430 (K)

Stock Financials

EPS -0.84
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.11
Profit Margin (%) -260.3
Operating Margin (%) -231.6
Return on Assets (ttm) -22.3
Return on Equity (ttm) -84.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.37
Sales Per Share 0.27
EBITDA (p.s.) -0.64
Qtrly Earnings Growth 0
Operating Cash Flow -55 (M)
Levered Free Cash Flow -45 (M)

Stock Valuations

PE Ratio -17.48
PEG Ratio 0
Price to Book value 13.22
Price to Sales 53.32
Price to Cash Flow -29.93

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.